Efficacy and safety of pertuzumab for HER2 positive metastatic breast cancer: a single institution experience

被引：0
|
作者：
Hara, Fumikata [1 ]
Aogi, Kenjiro [1 ]
Takashima, Seiki [1 ]
机构：
[1] Shikoku Canc Ctr, Breast Oncol, Matsuyama, Ehime, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-5-1
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [1] Tolerability of pertuzumab in older adults with HER2 positive breast cancer: A single institution experience
    Williams, Nicole
    Warmbier, Austin
    Doto, Dureti
    Palettas, Marilly
    Stephens, Julie
    Quiroga, Dionisia
    Johnson, Kai
    Pariser, Ashley
    Cherian, Mathew
    Sardesai, Sagar
    Stover, Daniel
    Gatti-Mays, Margaret
    Wesolowski, Robert
    Ramaswamy, Bhuvana
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [2] EFFICACY AND SAFETY OF TRASTUZUMAB IN SMALL HER2 POSITIVE TUMORS. A SINGLE INSTITUTION EXPERIENCE
    Sano, M. V.
    Taibi, E.
    Ali, M.
    Chiarenza, M.
    Clementi, S.
    Caruso, M.
    Aiello, R. A.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 104 - 104
  • [3] Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience
    Bahceci, Aykut
    Paydas, Semra
    Ak, Naziye
    Ferhatoglu, Ferhat
    Saip, Pinar Mualla
    Seydaoglu, Gulsah
    Bilici, Mehmet
    Simsek, Melih
    Tekin, Salim Basol
    Calikusu, Zuleyha
    Yavuz, Sinan
    Sahin, Ahmet Bilgehan
    Cubukcu, Erdem
    Evrensel, Turkkan
    Degirmencioglu, Serkan
    Demiray, Atike Gokcen
    Yumuk, Perran Fulden
    Alan, Ozkan
    Cikman, Duygu Ilke
    Demirelli, Fuat Hulusi
    Kostek, Osman
    Gokyer, Ali
    Dogan, Mutlu
    Bal, Oznur
    Cakar, Burcu
    Gokmen, Erhan
    Yamac, Deniz
    Korkmaz, Taner
    Aliyev, Altay
    Keskin, Ozge
    Urvay, Semiha
    Buyuksimsek, Mahmut
    Karadeniz, Cemile
    Yildiz, Birol
    Cinkir, Havva Yesil
    Demir, Hacer
    Beypinar, Ismail
    Karacin, Cengiz
    Eser, Kadir
    Baykara, Meltem
    Kilickap, Saadettin
    Okutur, Kerem
    Bulut, Gulcan
    Alkan, Ali
    Arpaci, Erkan
    Pilanci, Kezban Nur
    Demir, Atakan
    Isik, Deniz
    Yildirim, Nilgun
    [J]. CANCER INVESTIGATION, 2021, 39 (6-7) : 473 - 481
  • [4] Pertuzumab, Trastuzumab, Docetaxel: a single istitution clinical exeperience for Her2 positive metastatic breast cancer (mBC)
    Martines, C.
    Lavenia, G.
    Salice, P.
    Latteri, F.
    Commendatore, O.
    Sambataro, D.
    Burrafato, G.
    Mattina, M.
    Amadio, P.
    Bordonaro, R.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] HER2 LOW METASTATIC BREAST CANCER PATHOLOGICAL AND CLINICAL CHARACTERISTICS: A SINGLE MEXICAN INSTITUTION EXPERIENCE
    Tereza Nieto-Coronel, Maria
    Arce-Salinas, Claudia
    Tabares-Nanez, Ariana
    Curigliano, Giuseppe
    [J]. BREAST, 2023, 71 : S48 - S48
  • [6] SAFETY OF TRASTUZUMAB AND PERTUZUMAB FOR PATIENTS WITH PREVIOUSLY TREATED HER2 POSITIVE ADVANCED BREAST CANCER
    Sakaguchi, Haruna
    Ishihara, Mikiya
    Sawaki, Akihiko
    Nagaharu, Keiki
    Oda, Hiroyasu
    Sugawara, Yumiko
    Tamaru, Satoshi
    Yamashita, Yoshiki
    Mizuno, Toshiro
    Katayama, Naoyuki
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [7] Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience
    Omarini, C.
    Medici, G.
    Guaitoli, G.
    Iattoni, E.
    Moscetti, L.
    Balduzzi, S.
    Cascinu, S.
    Piacentini, F.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [8] Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer
    Gleeson, Jack Patrick
    Keegan, Niamh M.
    Morris, Patrick G.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (03) : 251 - 262
  • [9] The efficacy of trastuzumab, pertuzumab, and docetaxel in patients with HER-2-positive metastatic breast cancer
    Liem, Jean A.
    Kurniawan, Andree
    Christiano, Joysya
    Argo, Teresa M.
    Law, Natasha K.
    Asafia, Darlene
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S538 - S538
  • [10] Pertuzumab (Perjeta) for HER2-Positive Metastatic Breast Cancer
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2012, 54 (1395): : 59 - 60
12345